US Market Report for Psoriasis Immunology Drugs 2018 – MedCore – Markets Insider

NEW YORK, Nov. 6, 2017 /PRNewswire/ —

General Report Contents
– Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends

Read the full report: https://www.reportlinker.com/p05175237

– Market Drivers & Limiters for each chapter segment
– Competitive Analysis for each chapter segment
– Section on recent mergers & acquisitions

The typical life cycle of a healthy skin cell is about one month, but in people with psoriasis this process may take just a few days. This rapid overproduction leads to the build-up of skin cells because they do not have time to fall off. In most cases psoriasis can be diagnosed during the skin examination by dermatologist. In some cases, psoriasis can look like eczema and may require additional diagnostic tests, including biopsy, blood tests and X-rays.

Treating options vary depending on the level of pain and swelling. Non-steroidal anti-inflammatory drugs (ibuprofen, Motrin or Advil) or naproxen (Aleve) are used as initial treatment. In more severe cases disease modifying anti-rheumatic drugs (DMARDs) may be prescribed. DMARDs include sulfasalazine, methotrexate, cyclosporine and leflunomide. Other options are biologic medications, including HUMIRA® (adalimumab), Enbrel® (etanercept), SIMPONI® (golimumab), CIMZIA® (certolizumab), STELARA® (ustekinumab) and REMICADE® (infliximab) that are indicated for the both arthritis and skin psoriasis treatment.
The most recent developments include Cosentyx® (secukinumab), a biologic injection manufactured by Novartis for the treatment of psoriatic arthritis and launched in 2015. Cosentyx® is currently approved in more than 75 countries for the treatment of moderate-to-severe plaque psoriasis. The product is available in the European Union countries, Japan, Switzerland, Australia, the United States and Canada.

Abstract
Psoriasis (PsO) is a chronic autoimmune disease that results from the overproduction of skin cells that causes redness and inflammation. The disease typically affects elbows, knees or scalp, but can appear on any location. Psoriasis is not contagious. The disease is usually associated with other serious health conditions, such as diabetes, heart disease and depression.

There are several types of psoriasis; the most common are plaque psoriasis, guttate psoriasis, pustular psoriasis, inverse psoriasis and erythrodermic psoriasis. Plaque psoriasis usually results in patches of thick, red or inflamed skin covered with silvery scales known as plaques that can crack and bleed. Guttate psoriasis is more common in children and it causes small pink spots at the site of the torso, arms and legs. Pustular psoriasis causes is more common in adults and appears as a white blisters of non-infectious pustules surrounded by red inflamed skin. Inverse psoriasis causes bright areas of red, shiny and inflamed skin. Erythrodermic psoriasis usually covers large sections of the body at once and is very rare.
Another type of psoriasis condition is a psoriatic arthritis (PsA). It is also a chronic arthritis condition. PsA usually affect people with skin psoriasis.

Scope
2014-2024

Read the full report: https://www.reportlinker.com/p05175237

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

https://www.reportlinker.com

__________________________
Contact Clare: rel=”nofollow”>clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/us-market-report-for-psoriasis-immunology-drugs-2018—medcore-300550617.html

SOURCE Reportlinker

This Article Was Originally From *This Site*

Powered by WPeMatico